Visiongain Report Claims There is Huge Potential Within the $266bn Biologicals Market
LONDON, Oct. 28, 2019 /PRNewswire/ -- The global biologics market is estimated to reach $266bn in 2024. The market is expected to grow at a CAGR of 4.8% from 2019 to 2024. In 2018, the monoclonal antibodies submarket held 36% share of the global biologics market.
https://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 327-page report you will receive 182 charts- all unavailable elsewhere.
The 328-page Visiongain report provides clear detailed insight into the global biologics market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
To request sample pages from this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website: https://www.visiongain.com/report/biologics-market-trends-and-forecasts-2019-2029/#download_sampe_div
Report Scope
-- Global Biologics Market outlook from 2019-2029
-- Global Biologics Submarkets analysis and forecast from 2019-2029:
-- Protein therapeutics, with sub-forecasting for insulin, other recombinant hormones, plasma and recombinant coagulating factors, interferons, enzyme replacement and other agents
-- Monoclonal antibodies (mAbs)
-- Fusion proteins
-- Regenerative medicine, with sub-forecasting for stem cell treatment, tissue engineering and gene therapy
-- Vaccines
-- Analysis and forecast from 2019-2029 for selected leading biologics in the market:
-- Lantus
-- NovoLog/NovoRapid
-- Humalog
-- Avonex
-- Rebif
-- Humira
-- Remicade
-- Tysabri
-- Herceptin
-- Kadcyla
-- Perjeta
-- Enbrel
-- Eylea
-- OsteoCel Plus
-- Trinity Evolution and Trinity Elite
-- Apligraf
-- Dermagraft
-- IMLYGIC
-- This report provides individual revenue forecasts from 2018-2028 for these national markets:
-- The US
-- Japan
-- Germany
-- France
-- UK
-- Italy
-- Spain
-- China
-- India
-- Russia
-- Brazil
-- Our study discusses the selected leading companies:
-- AbbVie
-- Alexion Pharmaceuticals
-- Amgen
-- AstraZeneca
-- Bayer
-- Celgene Corporation
-- Eli Lilly
-- Gilead Sciences
-- GlaxoSmithKline (GSK)
-- Johnson & Johnson
-- Merck & Co., Inc.
-- Novartis
-- Novo Nordisk
-- Pfizer
-- Precision Biologics
-- Roche
-- Samsung Biologics
-- Sanofi S.A.
-- Takeda
-- UCB SA
-- This report discusses factors that drive and restrain this market. As well as opportunities and trends in this market.
-- This report discusses the SWOT and STEP Analysis of the biologics market.
-- Key questions answered by this report:
-- What is the current size of the total global biologics market? How much will this market be worth from to 2029?
-- What are the main drivers and restraints that will shape the overall biologics market over the next ten years?
-- What are the main segments within the overall biologics market? How much will each of these segments be worth for the period to 2029? How will the composition of the market change during that time, and why?
-- What factors will affect each of the different segments of the market over the next ten years?
-- What are the largest national markets for biologics? What is their current status and how will they develop over the next ten years? What are their forecasts for 2018 to 2029?
-- What are the leading products? What are their revenues and latest developments? How will the revenues for some of the leading products change over the next ten years?
-- Who are the most prominent companies, and what are their activities and outlooks?
-- What are some of the most prominent biologics currently in development?
-- What are the main trends that will affect the biologics market between 2018 and 2029?
-- What are the main strengths, weaknesses, opportunities and threats for the market?
-- What are the social, technological, economic and political influences that will shape this market over the next ten years?
To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website: https://www.visiongain.com/report/biologics-market-trends-and-forecasts-2019-2029/
Did you know that we also offer a report add-on service? Email sara.peerun@visiongain.com to discuss any customized research needs you may have.
Companies covered in the report include:
3SBio
AbbVie
Ablynx
Acceleron Pharma
Accord Healthcare
Aché
Actavis
Adaptive Biotechnologies Corporation
Advanced BioHealing
Advantagene
Advaxis, Inc.
Afferent Pharmaceuticals
Alder Biopharmaceuticals
Alector
Allergan
Alteogen
Amega Biotech
Amgen
AM?Pharma B.V.
Anacor Pharmaceuticals, Inc.
AnGes
Anthera Pharmaceuticals
Apceth
Apeiron Biologics
Apotex
Argenx
ARMO BioSciences, Inc.
Aryogen
Aspen Global Incorporated
Astellas Pharma
AstraZeneca
AurKa Pharma, Inc.
Aventis
Avita Medical
Bamboo Therapeutics, Inc.
Banner Alzheimer's Institute
Basilea Pharmaceutica Ltd.
Baxalta
Bayer
Beijing Four Rings
Beijing SL Pharmaceutical
Benda Pharmaceuticals
Biocad
BioCardia
Biocon
Biodel
Biogen
Bionovis
Biopartners
BioPharma
Biosidus
Biotest
Bioton
BioXpress Therapeutics
Boehringer Ingelheim
BrainStorm Cell Therapeutics
Bristol-Myers Squibb (BMS)
Cambridge Antibody Technology
cCAM Biotherapeutics
CCL Pharmaceuticals
Celgene Corporation
Celltrion
CEL-SCI
Centocor Ortho Biotech
Children's Oncology Group
CHMP
Chugai
CinnaGen
ClinImmune Labs
CSL Behring
CT Arzneimittel
CureVac AG
Cystic Fibrosis Foundation Therapeutics Inc
CytomX Therapeutics
Daiichi Sankyo Company, Limited
Dako
Dendreon
Dezima Pharma B.V.
DNAtrix
Dong-A Pharmaceutical
Dr. Reddy's Laboratories
Dynavax Technologies Corporation
Eisai Co., Ltd.
Eli Lilly and Company
Emcure Pharmaceuticals
EMS
Epirus
Europharm
Evotec
FDA
FibroGen
FierceBiotech
Finox Biotech
Flatiron Health
Foundation Medicine, Inc.
Fuji Pharma
Galencia
Gan & Lee
GE Healthcare
Genentech
Gennova
GenSci
Genzyme
Gilead Sciences
GlaxoSmithKline (GSK)
Hangzhou Jiuyuan Gene Engineering Co.
Hanwha Chemical
Harpoon Therapeutics
Harrisvaccines Inc.
Heptares Therapeutics
Hexal
Hindustan Antibiotic
Histogenics
Hospira, Inc.
Human Genome Sciences
Humana Inc.
Hypermarcas
IBM Watson Health
ICU Medical Inc.
Ignyta, Inc.
Immatics Biotechnologies GmbH
Immune Design
Immunex Corporation
Immunocore Limited
Incyte Corporation
Innovare R&D
Intas Pharmaceuticals
IOmet Pharma
Ipsen
Isis Pharmaceuticals, Inc.
Janssen
JingYuan Bio
Johnson & Johnson
Kite Pharma
Kyowa Hakko Kirin
Laboratorios Delta
LG Life Sciences
LifeSouth Community Blood Centers
Lonza
Luye Pharma Group, Ltd.
M2Gen
MacroGenics, Inc.
Massachusetts General Hospital
Medice
MEDICE Arzneimittel Pütter
MedImmune
MEDIPOST
Medivation, Inc.
Medtronic
Merck & Co., Inc.
Merck KGaA
Merz Pharma
Mirati Therapeutics, Inc.
Mitsubishi Tanabe
Mochida Pharmaceutical
Moderna Therapeutics
Mylan
NanoString Technologies, Inc.
NGM Biopharmaceuticals, Inc.
Nippion Kayaku
Northwestern University
Novartis
Novo Nordisk
NuVasive
Oanda
Organogenes
OrLife Bio
Orthofix
Orygen
Peregrine Pharmaceuticals, Inc.
Pfizer
Pharmacyclics
Pharmicell
Pharmstandard
Plexxikon Inc.
Porbiomed
Portola Pharmaceuticals Inc.
Premier Inc.
Principia
Probiomed
Protein Sciences
Proteon Therapeutics
Qilu Pharmaceutical
Ranbaxy
Ratiopharm
Redvax GmbH
Regeneron Pharmaceuticals, Inc.
Regenerys
Reliance Life Sciences
Rentschler Biotechnologie.
Rigontec
Roche
Samsung Bioepis
Sandoz
Sangamo Therapeutics, Inc.
Sanofi
Schering-Plough
SciGen
Shandong Kexing Pharma
Shanghai CP Guojian Pharmaceutical
Shanghai Fosun
Shanghai Sunway Biotech
Shantha Biotechnics
Shenzhen SiBiono GeneTech
Shire
Sicor Biotech
Sigilon Therapeutics
Simcere Pharmaceutical Group
Smith and Nephew
Spark Therapeutics
Stada
Stemcentrx
Stragen Pharma
Stratatech Corporation
Swiss Re
Takeda Pharmaceutical Company Limited
TESARO, Inc.
TetraLogic Pharmaceuticals Corporation
Teva
Tianjin Hualida Biotechnology
TiGenix
Tonghua Dongbao
Trophos
Turnstone Biologics
UCB
União Química
UniQure
Valeant Pharmaceuticals
Vertex Pharmaceuticals
Viralytics Limited
Vital Therapies Inc.
Voyager Therapeutics
Wockhardt
Wyeth-Ayerst Laboratories
Xencor, Inc.
Xiamen Amoytop Biotech
XO1 Limited
Zenotech
ZS Pharma
Zuventus
Zydus Biovation
Zydus Cadila
List of Organizations Mentioned in the Report
Agência Nacional de Vigilância Sanitária (ANVISA)
Australia's Walter and Eliza Hall Institute
Boston Children's Hospital
Center for Disease Prevention and Control (CDC)
Central Drugs Standard Control Organisation
China Food and Drug Administration
Duke University School of Medicine
EMA (European Medicines Agency)
European Commission (EC)
European Federation of Pharmaceutical Industries and Associations
Harvard University
Human Stem Cells Institute
International Myeloma Foundation
Johns Hopkins
Musculoskeletal Transplant Foundation (MTF)
National Cancer Institute
New York Blood Center
NHS
NICE
Rice University
Saudi Food and Drug Authority
SSN Cardinal Glennon Children's Medical Center
Stanford University
The European Generic medicines Association (EGA)
The European Group for Blood and Marrow Transplantation (EBMT)
The U.S. President's Emergency Plan for AIDS Relief (PEPFAR)
The University of Manchester
The University of Texas
The University of Texas MD Anderson Cancer Center
Toronto University
Toronto University
UCSF (University of California, San Francisco)
United Therapeutics
University of California, Berkeley
University of Colorado Cord Blood Bank
University of Tokyo
US Center for Disease Prevention and Control (CDC)
US Food and Drug Administration
Walter and Eliza Hall Institute
World Bank
World Health Organization (WHO)
Yonsei University
To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com
Related reports:
Global Macular Degeneration (AMD) and Other Retinal Diseases Drugs Industry and Market 2019-2029
Global Stem Cell Technologies and Applications Market 2019-2029
Global Influenza Vaccines Market Outlook 2019-2029
Global Precision Medicine Market Forecast 2019-2029
Global Vaccines Sales Market Forecast 2019-2029
View original content:http://www.prnewswire.com/news-releases/visiongain-report-claims-there-is-huge-potential-within-the-266bn-biologicals-market-300945079.html
SOURCE Visiongain
